Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis
- PMID: 25487560
- PMCID: PMC4260225
- DOI: 10.1038/srep07394
Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis
Abstract
Patients with schizophrenia have a higher risk for cardiovascular disease (CVD) than the general population. Research has suggested that autonomic imbalance is a common pathway to increased morbidity and mortality for CVD. Heart rate variability (HRV) analysis is a non-invasive method that assesses autonomic imbalance, and low HRV is correlated with high cardiovascular risk. Olanzapine, a widely used antipsychotic drug, is considered to have good cardiac safety because of not causing significant corrected QT-interval (QTc) prolongation; however, it is still unclear whether olanzapine affects HRV. We recruited 83 patients with schizophrenia who were medication-free for at least 1 month and tested their HRV at the baseline and 4 weeks after treatment with olanzapine. We found that patients who had substantial weight gain (EWG) manifested significantly lower HRV than those who had non-substantial weight gain (NWG) and that HRV decrease was positively correlated to an increase in body mass index (BMI) and weight gain. Our results indicate that olanzapine-induced weight gain may play an important role in its potential cardiovascular risk. Since olanzapine has a very high potential for weight gain compared with other antipsychotics, further research is needed to explore its cardiovascular safety profile, specifically long-term cardiac safety.
Figures

Similar articles
-
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.J Clin Psychiatry. 2005 Nov;66(11):1468-76. doi: 10.4088/jcp.v66n1118. J Clin Psychiatry. 2005. PMID: 16420086 Clinical Trial.
-
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000. Clin Drug Investig. 2011. PMID: 21495734 Review.
-
Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.Med Sci Monit. 2006 Feb;12(2):BR47-50. Epub 2006 Jan 26. Med Sci Monit. 2006. PMID: 16449941
-
Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain.Hum Psychopharmacol. 2011 Jun-Jul;26(4-5):332-7. doi: 10.1002/hup.1210. Epub 2011 Jun 22. Hum Psychopharmacol. 2011. PMID: 21695734
-
[Antipsychotics--clever choices].Lakartidningen. 2007 Feb 14-20;104(7):504-8. Lakartidningen. 2007. PMID: 17375681 Review. Swedish. No abstract available.
Cited by
-
Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis.J Psychiatry Neurosci. 2016 Mar;41(2):89-104. doi: 10.1503/jpn.140217. J Psychiatry Neurosci. 2016. PMID: 26447819 Free PMC article.
-
Vitamin D supplementation is effective for olanzapine-induced dyslipidemia.Front Pharmacol. 2023 Feb 21;14:1135516. doi: 10.3389/fphar.2023.1135516. eCollection 2023. Front Pharmacol. 2023. PMID: 36895943 Free PMC article.
-
Altered Heart Rate Variability During Rest in Schizophrenia: A State Marker.Cureus. 2023 Aug 26;15(8):e44145. doi: 10.7759/cureus.44145. eCollection 2023 Aug. Cureus. 2023. PMID: 37753044 Free PMC article.
-
Olanzapine-induced cardiomyopathy: A mimicker of obesity cardiomyopathy?Clin Cardiol. 2024 May;47(5):e24278. doi: 10.1002/clc.24278. Clin Cardiol. 2024. PMID: 38767024 Free PMC article. Review.
-
Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study.BMJ Open. 2017 Dec 6;7(12):e018209. doi: 10.1136/bmjopen-2017-018209. BMJ Open. 2017. PMID: 29217725 Free PMC article.
References
-
- Koponen H. et al. Schizophrenia and sudden cardiac death: a review. Nord J Psychiatry 62, 342–345 (2008). - PubMed
-
- Ifteni P., Correll C. U., Burtea V., Kane J. M. & Manu P. Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. Schizophr Res 155, 72–76 (2014). - PubMed
-
- Lin S. T. et al. Association Between Antipsychotic Use and Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study. Circulation 130, 235–243 (2014). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources